- - Wednesday, May 29, 2019

ANALYSIS/OPINION:

Sens. John Cornyn, Texas Republican, and Richard Blumenthal, Connecticut Democrat, claim that their new bill — the Affordable Prescriptions for Patients Act — will expand access to needed medicines for American patients. But in reality, the bill is poised to do the exact opposite.

Mr. Cornyn and Mr. Blumenthal want to target the drug industry for “anti-competitive abuses of the patent system.” The chief consequence of their reform, however, will be to deter pharmaceutical firms from investing in new drugs, or even improving on existing medicines.

American patients will suffer in the process.

The bill is premised on the idea that drug companies are gaming the Intellectual Property (IP) system by making incremental changes to drugs they have already patented. As Mr. Cornyn and Mr. Blumenthal see things, such behavior is merely a way of driving off competition from less-expensive generics, thereby inflating drug costs for patients.

The Affordable Prescriptions for Patients Act addresses this perceived abuse by empowering the Federal Trade Commission (FTC) to bring antitrust suits against pharmaceutical companies who engage in this practice.



But, plainly speaking, nearly every assumption behind the bill is fundamentally flawed. For starters, the reform takes for granted that any alterations or refinements to an existing medicine automatically amounts to an anti-competitive ploy, when in fact there are countless reasons to engage in such work — starting with better treatments for patients.

For instance, a drug firm might develop a time-release version of a medicine to make it easier and safer for patients to take. Or it might create new dosage forms entirely, allowing patients to take a pill or wear a patch instead of having the medicine administered intravenously. Similarly, researchers could find a new combination therapy that involves taking multiple already-available drugs in a specific sequence.

Advances like these can drastically benefit patients, whether by improving outcomes, reducing side-effects, or simply making a drug regimen more convenient.

Consider the difference between traveling to a doctor’s office to receive IV chemotherapy and taking a chemotherapy pill. For a patient who lives far away from a medical facility, or has trouble moving around, this new dosage form can be life-changing. And it’s only reasonable that drug companies who invest in such improvement are able to patent their discoveries.

A bill that penalizes such work will ensure that legitimate enhancements of existing products aren’t pursued — and patients will be worse off as a result.

It’s also not clear how developing a new version of an old drug impedes access to generics. After all, these improved medicines don’t extend the patent on the original drug. Any firm looking to release a lower-cost generic of a drug’s earlier version is free to do so, as many in fact do.

Indeed, though Sens. Cornyn and Blumenthal paint brand-name drug companies as monopolists, the fact is that roughly 80 percent of prescriptions filled in the United States are generics. So the notion that generic drugmakers are being unfairly kept out the market simply doesn’t comport with the facts.

What’s most troubling about the Cornyn-Blumenthal reform, however, is the threat it poses to America’s patent system, an institution that’s essential to drug discovery.

It takes a decade or more to bring a single new drug to market, and costs, on average, $2.6 billion. That process almost always involves numerous false starts and dead ends — only 1 in 10 drugs that reach clinical trials are ultimately approved.

Without the ability to protect their inventions through reliable IP laws, drug companies would have far less reason to expend the resources necessary to make genuine breakthroughs.

That would be disastrous for patients, especially those suffering from conditions for which no suitable treatment yet exists. Just think of those suffering from Alzheimer’s, a disease which afflicts 10 percent of Americans over 65, and for which a new drug hasn’t been approved in more than 15 years.

The Affordable Prescriptions for Patients Act would do little to expand access to generic drugs. But it would undermine an IP system that makes medical progress possible in the first place, leaving millions much worse off as a result. What Sens. Cornyn and Blumenthal need is an innovative dose of reality.

• Peter J. Pitts, a former FDA associate commissioner, is president of the Center for Medicine in the Public Interest.

Copyright © 2019 The Washington Times, LLC. Click here for reprint permission.

The Washington Times Comment Policy

The Washington Times welcomes your comments on Spot.im, our third-party provider. Please read our Comment Policy before commenting.

 

Click to Read More and View Comments

Click to Hide